Table 1.
Demographics and baseline clinical features of single-route prophylaxis recipients
| Characteristic | Overall (n = 1130) | IT (n = 894) | IV (n = 236) | P |
|---|---|---|---|---|
| Male sex, n (%) | 666 (58.9) | 540 (60.4) | 126 (53.4) | .051 |
| Median age, y (range) | 62 (18-86) | 62 (18-86) | 60 (20-82) | .02 |
| <70, n (%) | 852 (75.4) | 658 (73.6) | 194 (82.2) | Ref |
| ≥70, n (%) | 278 (24.6) | 236 (26.4) | 42 (17.8) | .007 |
| ECOG PS 0-1, n (%) | 844 (80.8) | 669 (80.1) | 175 (83.7) | .24 |
| Baseline renal impairment, n (%) | 172 (16.8) | 144 (17.8) | 28 (13.1) | 0.1 |
| B symptoms, n (%) | 415 (38.3) | 314 (36.6) | 101 (44.7) | .03 |
| Serum LDH, n (%) | ||||
| Not elevated | 339 (31.3) | 262 (30.5) | 77 (34.4) | Ref |
| Elevated, <3× ULN | 598 (55.2) | 480 (55.8) | 118 (52.7) | .58 |
| Elevated, ≥3× ULN | 147 (13.6) | 118 (13.7) | 29 (13.0) | .69 |
| Missing/unknown | 46 (4.1) | 34 (3.8) | 12 (5.1) | .61 |
| Stage, n (%) | ||||
| Limited (I-II) | 227 (20.1) | 176 (19.7) | 51 (21.6) | Ref |
| Advanced (III-IV) | 903 (79.9) | 718 (80.3) | 185 (78.4) | 0.51 |
| No. EN sites, n (%) | ||||
| 0 | 190 (16.8) | 174 (19.5) | 16 (6.8) | Ref |
| 1 | 523 (46.3) | 415 (46.4) | 108 (45.8) | .051 |
| ≥2 | 417 (36.9) | 305 (34.1) | 112 (47.5) | <.0001 |
| EN site(s) involved, n (%) | ||||
| Renal/adrenal | 133 (11.8) | 107 (12.0) | 26 (11.0) | .69 |
| Testis | 69 (6.1) | 44 (4.9) | 25 (10.6) | .001 |
| Breast | 34 (3.0) | 21 (2.4) | 13 (5.5) | .01 |
| Sinus | 82 (7.3) | 58 (6.5) | 24 (10.2) | .053 |
| Bone marrow | 124 (11.0) | 95 (10.6) | 29 (12.3) | .47 |
| CNS-IPI score, n (%) | ||||
| 0-1 (low) | 196 (18.4) | 151 (19.2) | 45 (19.2) | Ref |
| 2-3 (moderate) | 546 (51.4) | 432 (51.4) | 114 (48.5) | .33 |
| ≥4 (high) | 321 (30.2) | 245 (29.6) | 76 (32.3) | .67 |
| Histology, n (%) | ||||
| DLBCL | 750 (67.0) | 575 (65.0) | 175 (74.5) | Ref |
| HGBL | 305 (27.2) | 270 (30.5) | 35 (14.9) | <.0001 |
| Transformed FL | 43 (3.8) | 28 (3.2) | 15 (6.4) | .15 |
| Other | 22 (1.9) | 10 (1.1) | 12 (5.1) | .01 |
| Cell of origin (DLBCL only), n (%) | ||||
| Germinal center (GCB) | 340 (45.3) | 258 (44.9) | 82 (46.9) | Ref |
| Non-GCB | 316 (42.1) | 248 (43.1) | 68 (38.9) | .43 |
| Double-hit status, n (%) | ||||
| DH evaluable | 875 (77.4) | 687 (78.5) | 188 (21.5) | Ref |
| Confirmed DH /TH* | 243 (27.7) | 223 (32.5) | 20 (10.6) | <.0001 |
| Not DH evaluable | 255 (22.6) | 207 (23.2) | 48 (20.3) | .36 |
| Frontline chemotherapy regimen, n (%) | ||||
| R-CHOP | 536 (47.5) | 377 (42.2) | 159 (67.4) | Ref |
| R-EPOCH (+/− dose adjustment) | 509 (45.1) | 441 (49.4) | 68 (28.8) | .04 |
| Other | 85 (7.4) | 75 (8.4) | 9 (3.8) | .09 |
All listed P values are 2-sided.
CNS, central nervous system; DH, double-hit; DLBCL, diffuse large B-cell lymphoma; EN, extranodal; FL, follicular lymphoma; HGBL, high grade B-cell lymphoma; iNHL, indolent non-Hodgkin lymphoma; IPI, international prognostic index; IT, intrathecal; LDH, lactate dehydrogenase; TH, triple hit; ULN, upper limit of normal.
*
Percentage of DH evaluable patients. Percentages are otherwise referenced within each column.